China's CanSino Biologics and a unit of Sinopharm said Wednesday they have applied for public use of their Covid-19 vaccines, and announced efficacy rates.

Sinopharm affiliate Wuhan Institute Of Biological Products said in a statement its vaccine's efficacy rate was 72.51 percent, while the overall efficacy for CanSino's stood at 65.28 percent after 28 days.

If their applications are successful, it would mean four of China's domestically developed vaccines are approved for public use.

Earlier this month, China's drug authorities gave conditional approval to Sinovac's CoronaVac jab, while the first green light went to another Sinopharm product in December.

The published efficacy rates of China's vaccines, however, remain behind rival jabs by Pfizer-BioNTech and Moderna, which have 95 percent and 94 percent rates respectively.

China has been racing to develop homegrown jabs, and set a goal to vaccinate 50 million people by mid-February -- with more than 40 million doses given as of February 9.

Its vaccination programme has initially been targeting key groups such as medical workers and people who work and study abroad, according to state media.

Wuhan Institute Of Biological Products cited late stage clinical trial data when releasing its vaccine's efficacy rate, saying it met the World Health Organization's "relevant technical standards".

In a separate filing, CanSino Biologics said interim data analysis of more than 40,000 subjects has been done.

It said its single-shot vaccine had 68.83 percent protective efficacy against all symptomatic cases after 14 days, and this dropped to 65.28 percent after 28 days.

The protective effects against severe disease was 95.47 percent after 14 days of receiving the jab and 90.07 after 28 days, said the company.

On Monday, Foreign Minister Wang Yi said China was providing free vaccines to 53 countries, and exporting vaccines to 22 nations who have made purchasing requests.

bys/mtp

CanSino Biologics Inc.

Related Links
Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola

Tweet

Thanks for being here; We need your help. The SpaceDaily news network continues to grow but revenues have never been harder to maintain. With the rise of Ad Blockers, and Facebook - our traditional revenue sources via quality network advertising continues to decline. And unlike so many other news sites, we don't have a paywall - with those annoying usernames and passwords. Our news coverage takes time and effort to publish 365 days a year. If you find our news sites informative and useful then please consider becoming a regular supporter or for now make a one off contribution.
SpaceDaily Contributor $5 Billed Once credit card or paypal		SpaceDaily Monthly Supporter $5 Billed Monthly paypal only

Privacy faces risks in tech-infused post-Covid workplace
Washington (AFP) Feb 21, 2021
People returning to work following the long pandemic will find an array of tech-infused gadgetry to improve workplace safety but which could pose risks for long-term personal and medical privacy. Temperature checks, distance monitors, digital "passports," wellness surveys and robotic cleaning and disinfection systems are being deployed in many workplaces seeking to reopen. Tech giants and startups are offering solutions which include computer vision detection of vital signs to wearables which ca ... read more